Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions

Biochemical Pharmacology
X J ZhouR Rahmani

Abstract

Vindesine biotransformation was investigated using a bank of human liver microsomes. The drug was converted into one major metabolite (M) upon incubation with the microsomes. Large interindividual variations were observed: vindesine biotransformation rates ranged from 1.2 to 12.9 pmol/min/mg protein. Vindesine metabolic processes followed Michaelis-Menten kinetics: Km = 24.7 +/- 9.4 microM, Vmax = 1.5 +/- 0.8 nmol/min/mg protein. The involvement of human cytochrome P450 3A isozymes in vindesine metabolism was demonstrated by: (1) competitive inhibition of vindesine biotransformation by compounds known to be specifically metabolized by human cytochrome P450 3A. Apparent Ki values were 3.6, 17.9 and 19.8 microM for quinidine, troleandomycin and erythromycin, respectively; (2) immunoinhibition of vindesine metabolism by polyclonal anti-P450 3A antibody; (3) significant correlation between immunoquantified P450 3A and vindesine biotransformation (r = 0.800, P < 0.001); and (4) significant correlation between erythromycin N-demethylase activity, which was supported by P450 3A in humans, and vindesine biotransformation (r = 0.853, P < 0.001). Other vinca alkaloids also exerted an inhibitory effect on vindesine biotransformation with ...Continue Reading

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·X J ZhouR Rahmani
Oct 1, 1990·European Journal of Drug Metabolism and Pharmacokinetics·X J ZhouR Rahmani
Jan 1, 1990·European Journal of Drug Metabolism and Pharmacokinetics·R RahmaniJ P Cano
Jan 1, 1987·Clinical Pharmacology and Therapeutics·M J RatainJ A Sinkule
Jan 1, 1984·Cancer Chemotherapy and Pharmacology·D V JacksonC L Spurr
Nov 15, 1984·Biochemical Pharmacology·C H KleinbloesemD D Breimer
Nov 1, 1984·European Journal of Cancer & Clinical Oncology·R RahmaniJ Barbet

❮ Previous
Next ❯

Citations

Jan 1, 1995·Cancer Chemotherapy and Pharmacology·A V BoddyJ R Idle
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·M A Sarkar
Jul 8, 2009·Applied Biochemistry and Biotechnology·Sepuri Asha, Maravajhala Vidyavathi
Nov 2, 1993·Biochemical Pharmacology·T WalleU K Walle
Dec 15, 1995·Toxicology·A P LiA Rasmussen
May 17, 2000·European Journal of Pharmacology·Y MitsunagaY Sawada
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L Iyer, M J Ratain
May 5, 1999·Critical Reviews in Oncology/hematology·C E GiddingS S de Graaf
May 5, 1998·Journal of Pharmacological and Toxicological Methods·R J Riley, D Howbrook
Jul 10, 2003·Lancet Neurology·Charles J VechtErik B Wilms
Dec 1, 1995·British Journal of Clinical Pharmacology·K T KivistöM Eichelbaum
Dec 23, 2006·Acta Pharmacologica Sinica·Xiao-Ping ZhaoGuang-Ji Wang
May 23, 1998·Annual Review of Pharmacology and Toxicology·K E Thummel, G R Wilkinson
Jun 27, 2002·Pediatric Research·Ellis GroningerSiebold de Graaf
Oct 21, 2010·The Annals of Pharmacotherapy·Nicola F SmithAlex Sparreboom
Dec 14, 2012·PloS One·Saskia PreissnerKarlheinz Seeger
Aug 12, 2003·Clinical Pharmacokinetics·Megan A Gibbs, Natilie A Hosea
Nov 4, 2005·Investigational New Drugs·Ron H N van Schaik
May 9, 2002·Drug Metabolism Reviews·Slobodan Rendic
Apr 20, 2007·Journal of Clinical Pharmacology·Dominique Levêque, François Jehl
Feb 12, 2014·Expert Opinion on Drug Metabolism & Toxicology·Rabih Said, Apostolia Maria Tsimberidou
Aug 1, 1997·Leukemia & Lymphoma·N Gökbuget, D Hoelzer
Dec 8, 2004·Critical Reviews in Oncology/hematology·E GroningerS S N de Graaf
May 1, 1996·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R L CheungD S Riddick
Jun 20, 1998·The Journal of Biological Chemistry·J M Huss, C B Kasper
Nov 5, 1999·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J C GorskiS D Hall
May 9, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jennifer B DennisonStephen D Hall
Mar 9, 2021·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yan JinShuiying Hu
Jan 1, 1995·Clinical Pharmacology and Therapeutics·K S LownP B Watkins
Dec 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ron H J Mathijssen, Ron H N van Schaik

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
K YamaguchiS Kobayashi
Fundamental & Clinical Pharmacology
Dominique Beulz-RichéDamrong Ratanasavanh
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
B J CusackR D Olson
© 2021 Meta ULC. All rights reserved